Investor profile

Jazz Pharmaceuticals

Global biopharmaceutical company (Nasdaq: JAZZ) that acquired Aerial BioPharma's narcolepsy asset ADX-N05 in 2014 and led the 2016 launch financing of the same team's next company, Arrivo BioVentures, with a $25 million commitment callable over five years, holding a board observer seat.

Corporate investor

Dublin, Ireland

Visit website

Directory portfolio

Companies connected here

A
Arrivo BioVentures
Clinical-stage drug developer with two candidates: forvisirvat (SP-624), a SIRT6 activator in Phase 2b/3 for major depressive disorder, and RABI-767 for predicted severe acute pancreatitis.

Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.